SCHEDULE: Eventide Asset Management Discloses Stake in Collegium Pharma

Eventide Asset Management, LLC, along with Finny Kuruvilla and Robin C. John, has filed a Schedule 13G, reporting beneficial ownership of 4.5% of Collegium Pharmaceutical, Inc. common stock as of March 31, 2026.

Summary

• Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph.D., and Robin C. John have jointly filed a Schedule 13G, indicating their beneficial ownership of Collegium Pharmaceutical, Inc. common stock.
• As of March 31, 2026, the reporting persons collectively beneficially own 1,424,282 shares of common stock.
• This represents 4.5% of the total class of securities outstanding.
• Eventide Asset Management, LLC holds sole voting and dispositive power over its shares, while Finny Kuruvilla and Robin C. John share voting and dispositive power over the same block of shares.
• The filing is made under Rule 13d-1(b), indicating the reporting persons are not acting as a group with the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership and does not contain operational or financial performance updates.

Positives

• Eventide Asset Management, LLC, Finny Kuruvilla, and Robin C. John have disclosed their significant stake in Collegium Pharmaceutical, Inc., providing transparency to the market.
• The reporting persons hold a substantial 4.5% stake, suggesting confidence in the company's prospects.

Risks

• The filing does not explicitly mention any risks associated with the investment or the company's operations.

Future Outlook

The filing does not contain any forward-looking statements or guidance from the company.

Management Comments

• Each of the persons filing this statement expressly disclaims the beneficial ownership of the securities covered by this statement and the filing of this report shall not be construed as an admission by such persons that they are the beneficial owners of such securities.
• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant individual holders who acquire more than 5% of a company's stock. This filing indicates Eventide Asset Management, along with associated individuals, has taken a notable position in Collegium Pharmaceutical, a company operating in the pharmaceutical sector.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant ownership stakes in Collegium Pharmaceutical, Inc.
• Management: Awareness of a substantial investor group holding 4.5% of the company's stock.

Next Steps

• The reporting persons will continue to hold their shares in Collegium Pharmaceutical, Inc.
• Any future changes in beneficial ownership exceeding reporting thresholds will require further filings.

Key Dates

Keywords

Colleigum Pharmaceutical, Schedule 13G, Eventide Asset Management, Finny Kuruvilla, Robin C. John, Beneficial Ownership, SEC Filing, Investment Holding